Carlos Morcillo-Suarez
Pompeu Fabra University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Carlos Morcillo-Suarez.
JAMA Neurology | 2009
Manuel Comabella; David Craig; Carlos Morcillo-Suarez; Jordi Río; Arcadi Navarro; Marta Fernández; Roland Martin; Xavier Montalban
BACKGROUND Interferon beta is 1 of 2 first-line treatments for relapsing-remitting multiple sclerosis (MS). However, not all patients respond to interferon beta therapy, and to date there is a lack of surrogate markers that reliably correlate with responsiveness to interferon beta therapy in MS. OBJECTIVE To identify allelic variants that influence response to interferon beta therapy in patients with MS. DESIGN Genome-wide scan. SETTING Academic research. Patients Two hundred patients having relapsing-remitting MS treated with interferon beta and having a follow-up period of at least 2 years were classified as responders or nonresponders to treatment based on stringent clinical criteria. MAIN OUTCOME MEASURES In the first phase of the study, a pooling-based genome-wide association study of 428 867 single-nucleotide polymorphisms (SNPs) was performed in 53 responders and 53 nonresponders to interferon beta therapy. After applying several selection criteria, 383 SNPs were individually genotyped in an independent validation cohort of 49 responders and 45 nonresponders to interferon beta therapy using a different genotyping platform. RESULTS Eighteen SNPs had uncorrected P < .05 associated with interferon beta responder status in the validation cohort. Of these, 7 SNPs were located in genes that code for alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid-type glutamate receptor GRIA3, type 1 interferon-related proteins ADAR and IFNAR2, cell cycle-dependent protein CIT, zinc finger proteins ZFAT and ZFHX4, and guanosine triphosphatase-activating protein STARD13. CONCLUSIONS This study supports an underlying polygenic response to interferon beta treatment in MS and highlights the importance of the glutamatergic system in patient response to interferon beta therapy.
Bioinformatics | 2008
Carlos Morcillo-Suarez; Josep Alegre; Ricardo Sangrós; Elodie Gazave; Rafael de Cid; Roger L. Milne; Jorge Amigo; Anna Ferrer-Admetlla; Andres Moreno-Estrada; Michelle Gardner; Ferran Casals; Anna Pérez-Lezaun; David Comas; Elena Bosch; Francesc Calafell; Jaume Bertranpetit; Arcadi Navarro
UNLABELLED Single nucleotide polymorphisms (SNPs) are the most widely used marker in studies to assess associations between genetic variants and complex traits or diseases. They are also becoming increasingly important in the study of the evolution and history of humans and other species. The analysis and processing of SNPs obtained thanks to high-throughput technologies imply the time consuming and costly use of different, complex and usually format-incompatible software. SNPator is a user-friendly web-based SNP data analysis suite that integrates, among many other algorithms, the most common steps of a SNP association study. It frees the user from the need to have large computer facilities and an in depth knowledge of genetic software installation and management. Genotype data is directly read from the output files of the usual genotyping platforms. Phenotypic data on the samples can also be easily uploaded. Many different quality control and analysis procedures can be performed either by using built-in SNPator algorithms or by calling standard genetic software. AVAILABILITY Access is granted from the SNPator webpage http://www.snpator.org.
Genome Research | 2011
Elodie Gazave; Fleur Darré; Carlos Morcillo-Suarez; Natalia Petit-Marty; Angel Carreño; Urko M. Marigorta; Oliver A. Ryder; Antoine Blancher; Mariano Rocchi; Elena Bosch; Carl Baker; Tomas Marques-Bonet; Evan E. Eichler; Arcadi Navarro
Copy number variants (CNVs) are increasingly acknowledged as an important source of evolutionary novelties in the human lineage. However, our understanding of their significance is still hindered by the lack of primate CNV data. We performed intraspecific comparative genomic hybridizations to identify loci harboring copy number variants in each of the four great apes: bonobos, chimpanzees, gorillas, and orangutans. For the first time, we could analyze differences in CNV location and frequency in these four species, and compare them with human CNVs and primate segmental duplication (SD) maps. In addition, for bonobo and gorilla, patterns of CNV and nucleotide diversity were studied in the same individuals. We show that CNVs have been subject to different selective pressures in different lineages. Evidence for purifying selection is stronger in gorilla CNVs overlapping genes, while positive selection appears to have driven the fixation of structural variants in the orangutan lineage. In contrast, chimpanzees and bonobos present high levels of common structural polymorphism, which is indicative of relaxed purifying selection together with the higher mutation rates induced by the known burst of segmental duplication in the ancestor of the African apes. Indeed, the impact of the duplication burst is noticeable by the fact that bonobo and chimpanzee share more CNVs with gorilla than expected. Finally, we identified a number of interesting genomic regions that present high-frequency CNVs in all great apes, while containing only very rare or even pathogenic structural variants in humans.
Clinical Biochemistry | 2009
Judit Marsillach; Gerard Aragonès; Raúl Beltrán; Joan Caballería; Juan Pedro-Botet; Carlos Morcillo-Suarez; Arcadi Navarro; Jorge Joven; Jordi Camps
AIMS We investigated the analytical performance of a new assay of the lactonase activity of paraoxonase-1 and its efficacy in the assessment of liver damage. DESIGN AND METHODS Serum lactonase activity was determined by the hydrolysis of 5-thiobutyl butyrolactone in 633 healthy individuals and 369 patients with chronic liver disease. Paraoxonase-1, 2, and 3 gene polymorphisms were analyzed by the MassArray method. RESULTS Linearity was up to 10 U/L. Detection limit was 0.12 U/L. Imprecision was < or = 17.7%. Lactonase values in our normal population were 5.99 (3.29-13.61) U/L. Lactonase activity showed a lower influence of genetic polymorphisms than the classical assay using paraoxon. Both measurements showed a similar efficiency in testing for liver dysfunction. CONCLUSION We report a reliable assay using a non-toxic substrate for the measurement of serum lactonase activity. The influence of genetic variability is low. The assay could be a useful addition to tests evaluating liver impairment.
Journal of Neuroimmunology | 2005
M. Camiña-Tato; Carlos Morcillo-Suarez; Arcadi Navarro; Marta Fernández; A. Horga; Xavier Montalban; Manuel Comabella
In the present study, we investigated the B-cell translocation gene 1 (BTG1) as a candidate for multiple sclerosis (MS) susceptibility. BTG1 is a member of a family of genes involved in the apoptotic process. We genotyped two SNPs of the BTG1 gene (rs731652 and rs12694) in 550 MS patients and 548 controls. For SNP rs731652, significant associations with relapse-onset MS were found at the allele and genotype levels when compared with controls. We identified a risk haplotype associated with relapse-onset MS. These findings support the hypothesis that BTG1 polymorphisms may influence genetic predisposition for MS, especially in relapse-onset MS patients.
European Journal of Neurology | 2013
S. Malhotra; Carlos Morcillo-Suarez; R. Nurtdinov; Jordi Río; E. Sarro; M. Moreno; Joaquín Castilló; Arcadi Navarro; X. Montalban; Manuel Comabella
Ubiquitin specific peptidase 18 (USP18) is a deubiquitinating enzyme that functions as a negative regulator of the type I interferon (IFN) signalling pathway and is specifically induced by type I IFNs. In the present study, previous observations by our group were expanded suggesting an implication of USP18 in multiple sclerosis (MS) based on the finding of a deficient expression of the gene in peripheral blood mononuclear cells from MS patients compared with healthy controls.
BMC Genomics | 2013
Javier Prado-Martinez; Irene Hernando-Herraez; Belen Lorente-Galdos; Marc Dabad; Oscar Ramirez; Carlos Baeza-Delgado; Carlos Morcillo-Suarez; Can Alkan; Fereydoun Hormozdiari; Emanuele Raineri; Jordi Estellé; Marcos Fernandez-Callejo; Mònica Vallés; Lars Ritscher; Torsten Schöneberg; Elisa de la Calle-Mustienes; Sònia Casillas; Raquel Rubio-Acero; Marta Melé; Johannes Engelken; Mario Cáceres; José Luis Gómez-Skarmeta; Marta Gut; Jaume Bertranpetit; Ivo Gut; Teresa Abello; Evan E. Eichler; Ismael Mingarro; Carles Lalueza-Fox; Arcadi Navarro
BackgroundThe only known albino gorilla, named Snowflake, was a male wild born individual from Equatorial Guinea who lived at the Barcelona Zoo for almost 40 years. He was diagnosed with non-syndromic oculocutaneous albinism, i.e. white hair, light eyes, pink skin, photophobia and reduced visual acuity. Despite previous efforts to explain the genetic cause, this is still unknown. Here, we study the genetic cause of his albinism and making use of whole genome sequencing data we find a higher inbreeding coefficient compared to other gorillas.ResultsWe successfully identified the causal genetic variant for Snowflake’s albinism, a non-synonymous single nucleotide variant located in a transmembrane region of SLC45A2. This transporter is known to be involved in oculocutaneous albinism type 4 (OCA4) in humans. We provide experimental evidence that shows that this amino acid replacement alters the membrane spanning capability of this transmembrane region. Finally, we provide a comprehensive study of genome-wide patterns of autozygogosity revealing that Snowflake’s parents were related, being this the first report of inbreeding in a wild born Western lowland gorilla.ConclusionsIn this study we demonstrate how the use of whole genome sequencing can be extended to link genotype and phenotype in non-model organisms and it can be a powerful tool in conservation genetics (e.g., inbreeding and genetic diversity) with the expected decrease in sequencing cost.
Journal of Immunology | 2010
Montse Camiña-Tato; Carlos Morcillo-Suarez; Marta F. Bustamante; Israel Ortega; Arcadi Navarro; Aura Muntasell; Miguel López-Botet; Alex Sánchez; Paco Carmona; Eva Julià; María Teresa Tortola; Laura Audí; Jorge R. Oksenberg; Roland Martin; Xavier Montalban; Manuel Comabella
The granule-dependent exocytosis pathway is an important mechanism to induce apoptosis by CD8+ T cells and NK cells and involves lytic molecules such as perforin. In the current study, we investigated the perforin 1 gene (PRF1) as a candidate for multiple sclerosis (MS) susceptibility in the Spanish population. We genotyped three PRF1 single nucleotide polymorphisms (rs885822, rs10999426, and rs3758562) in 420 patients with MS and 512 controls. Associations of PRF1 polymorphisms with the disease were restricted to male patients with MS, and the finding was consistently observed at the allele, genotype, and haplotype levels. Gender-associated differences were validated in an additional replication cohort comprised of 292 MS cases and 300 controls. In addition, we identified minor risk haplotypes strongly associated with male patients having primary progressive MS (PPMS). Further characterization of male patients with PPMS carrying the risk haplotypes by means of gene expression microarrays revealed overrepresentation of the cell killing gene ontology category among downregulated genes in these patients compared with male patients with PPMS carrying protective haplotypes. Moreover, PRF1 mRNA expression levels were significantly lower in patients with risk haplotypes, and changes in perforin protein expression by CD8+ T cells mirrored those observed in gene expression. These findings suggest a gender dimorphism in the PRF1 association with MS and point to the presence of a generalized defect in the expression of genes that code for proteins involved in cell killing in a subgroup of male patients with PPMS.
BMC Genomics | 2011
Urko M. Marigorta; Oscar Lao; Ferran Casals; Francesc Calafell; Carlos Morcillo-Suarez; Rui Faria; Elena Bosch; François Serra; Jaume Bertranpetit; Hernán Dopazo; Arcadi Navarro
BackgroundSearching for associations between genetic variants and complex diseases has been a very active area of research for over two decades. More than 51,000 potential associations have been studied and published, a figure that keeps increasing, especially with the recent explosion of array-based Genome-Wide Association Studies. Even if the number of true associations described so far is high, many of the putative risk variants detected so far have failed to be consistently replicated and are widely considered false positives. Here, we focus on the world-wide patterns of replicability of published association studies.ResultsWe report three main findings. First, contrary to previous results, genes associated to complex diseases present lower degrees of genetic differentiation among human populations than average genome-wide levels. Second, also contrary to previous results, the differences in replicability of disease associated-loci between Europeans and East Asians are highly correlated with genetic differentiation between these populations. Finally, highly replicated genes present increased levels of high-frequency derived alleles in European and Asian populations when compared to African populations.ConclusionsOur findings highlight the heterogeneous nature of the genetic etiology of complex disease, confirm the importance of the recent evolutionary history of our species in current patterns of disease susceptibility and could cast doubts on the status as false positives of some associations that have failed to replicate across populations.
Journal of Neuroimmunology | 2011
Sunny Malhotra; Carlos Morcillo-Suarez; David Brassat; Robert Goertsches; Jeannette Lechner-Scott; Elena Urcelay; Oscar Fernández; Jelena Drulovic; A. García-Merino; F. Martinelli Boneschi; Andrew T. Chan; Koen Vandenbroeck; Arcadi Navarro; Marta F. Bustamante; Jordi Río; D.A. Akkad; Giacomo Giacalone; Antonio Sánchez; Laura Leyva; Roberto Alvarez-Lafuente; Uwe K. Zettl; Jorge R. Oksenberg; X. Montalban; Manuel Comabella
Recent studies have revealed an association between interleukin 28B (IL28B) and response to IFN-alpha treatment in hepatitis C patients. Here we investigated the influence of IL28B polymorphisms in the response to interferon-beta (IFNβ) in multiple sclerosis (MS) patients. We genotyped two SNPs of the IL28B gene (rs8099917 and rs12979860) in 588 MS patients classified into responders (n=281) and non-responders (n=307) to IFNβ. Combined analysis of the study cohorts showed no significant associations between SNPs rs8099917 and rs12979860 and the response to treatment. These findings do not support a role of IL28B polymorphisms in the response to IFNβ in MS patients.